Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03252808
Recruitment Status : Active, not recruiting
First Posted : August 17, 2017
Last Update Posted : June 21, 2022
Sponsor:
Information provided by (Responsible Party):
Takara Bio Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Biological: TBI-1401(HF10) Drug: Gemcitabine Drug: Nab-paclitaxel Drug: TS-1 Phase 1

Detailed Description:

A Phase I, open-label, multi-center study to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer. Patients with stage IV must failed a gemcitabine based first-line chemotherapy.

Patients with stage III will receive the repeated intratumoral injection of TBI-1401(HF10) at recommended dose at 2-week intervals in combination with intravenous infusion of 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel at weekly for 3 weeks followed by 1 week rest.

Patients with stage IV will receive the repeated intratumoral injection of TBI-1401(HF10) at recommended dose at 2-week intervals in combination with oral of 40 - 60 mg TS-1 at twice daily for 4 weeks followed by 2 weeks rest.

Patients will receive the combination therapy of TBI-1401(HF10) + chemo for up to 1 year if eligible for treatment.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Combination With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Patients With Stage III or IV Unresectable Pancreatic Cancer.
Actual Study Start Date : September 25, 2017
Actual Primary Completion Date : February 19, 2020
Estimated Study Completion Date : March 31, 2035

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: TBI-1401(HF10) + Gem/nab-PTX
1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
 Biological: TBI-1401(HF10)
1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
Other Names:
  • HF10
  • canerpaturev

Drug: Gemcitabine
1000 mg/m^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
Other Name: Gemzar

Drug: Nab-paclitaxel
125 mg/m^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
Other Name: Abraxane
Experimental: TBI-1401(HF10) + TS-1 (primary)
1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
 Biological: TBI-1401(HF10)
1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
Other Names:
  • HF10
  • canerpaturev

Drug: TS-1
TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
Other Name: Tegafur-gimeracil-oteracil potassium
Experimental: TBI-1401(HF10) + TS-1 (primary and meta)
1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
 Biological: TBI-1401(HF10)
1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
Other Names:
  • HF10
  • canerpaturev

Drug: TS-1
TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
Other Name: Tegafur-gimeracil-oteracil potassium


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Dose Limiting Toxicity (DLT) [ Time Frame: Through 1st TBI-1401(HF10) injection to before 3rd injection (basically 4 weeks). ]
    Determine the recommended dose of TBI-1401(HF10) in combination with Gemcitabine and Nab-paclitaxel.


Secondary Outcome Measures :
  1. Adverse Events (AEs) [ Time Frame: Through 1st TBI-1401(HF10) injection to study completion (up to 13 month). ]
    Evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0).

  2. Objective response rate (ORR) by RECIST [ Time Frame: At 16 weeks and through study completion (up to 1 year). ]
    Overall tumor response evaluated by RECIST version 1.1

  3. Objective response rate (ORR) by irRECIST [ Time Frame: At 16 weeks and through study completion (up to 1 year). ]
    Overall tumor response evaluated by irRECIST.

  4. Progression-free survival (PFS) by RECIST [ Time Frame: Through disease progression (up to 1 year). ]
    Evaluation the time to progression during and after the treatment.

  5. Progression-free survival (PFS) by irRECIST [ Time Frame: Through disease progression (up to 1 year). ]
    Evaluation the time to progression during and after the treatment.


Other Outcome Measures:
  1. Overall survival (OS) [ Time Frame: From 1st treatment to death (up to 2 years). ]
    Evaluation the overall survival.

  2. 1 year survival rate [ Time Frame: for 1 year. ]
    Determine the 1 year survival rate of patient who received treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed unresectable pancreatic cancer (stage III or IV) based on the General Rules for the Study of Pancreatic Cancer (The 7th edition), and never received anti-cancer therapy (radiation therapy, chemotherapy, immunotherapy, surgery, clinical trials).
  • Patients with primary lesion will be intratumorally injectable for TBI-1401(HF10) by EUS (endoscopic ultrasound).
  • Patients must be ≧20 years of age.
  • Patients must have at least one measurable lesion evaluated by Computed Tomography (CT) scan on RECIST ver.1.1 at pre-treatment.
  • Patients must have a life expectancy ≧12 weeks.
  • Patients must have an ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0-1.
  • Patients demonstrated adequate organ function (≦7 days prior to treatment).
  • Females of childbearing potential must have a negative urine or serum pregnancy test within 1 week prior to start of treatment.
  • Patients must be able to understand the study and willing to sign a written informed consent document.

Exclusion Criteria:

  • Patients receiving anti-herpes medication within 1 week prior to TBI-1401(HF10) treatment (except local treatment such as ointment).
  • Patients with a significant tumor bleeding or coagulation abnormality that could not treat intratumoral injection or biopsy in safe.
  • Patients with clinically evident Hepatitis B surface antigen (HBs) positive, Hepatitis C virus (HCV) antibody positive and HSV-RNA positive, Human Immunodeficiency Virus (HIV) antibody positive.
  • Patients with the active symptom of Epstein-Barr virus (EBV) infection.
  • Patients with active CNS metastases.
  • Patients with ascites, except acceptable mild ascites.
  • Patients with multiple cancer.
  • Patients need to treat anticoagulant or antiplatelet agent.
  • Patients has a history of allergy for CT contrast agent, live vaccine, any drug excipients, Nab-paclitaxel, Gemcitabine, or any study drugs.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03252808


Locations
Layout table for location information
Japan
Clinical Site
Nagoya, Aichi, Japan
Clinical Site
Kashiwa, Chiba, Japan
Clinical Site
Yokohama, Kanagawa, Japan
Clinical Site
Chūōku, Tokyo, Japan
Clinical Site
Koto-Ku, Tokyo, Japan
Clinical Site
Chiba, Japan
Clinical Site
Nagoya, Japan
Clinical Site
Osaka, Japan
Sponsors and Collaborators
Takara Bio Inc.
Investigators
Layout table for investigator information
Study Director: Takara Bio Inc. Clinical Development & Strategy Division 2
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Takara Bio Inc.
ClinicalTrials.gov Identifier: NCT03252808    
Other Study ID Numbers: TBI1401-03
First Posted: August 17, 2017    Key Record Dates
Last Update Posted: June 21, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Takara Bio Inc.:
Unresectable pancreatic cancer
Metastatic pancreatic cancer
Pancreatic adenocarcinoma
TBI-1401(HF10)
HF10
Oncolytic virus
Oncolytic viral immunotherapy
 Gemcitabine
Nab-paclitaxel
Albumin-bound paclitaxel
Abraxane
Tegafur-gimeracil-oteracil potassium
TS-1
canerpaturev
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Paclitaxel
Tegafur
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
 Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs